-
1
-
-
77955635233
-
Cancer statistics
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-300.
-
(2010)
CA Cancer J Clin.
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
49549125242
-
Principles and practice of screening for disease
-
Wilson JM, Jungner YG. Principles and practice of screening for disease. WHO Chron. 1968;22(11):473.
-
(1968)
WHO Chron.
, vol.22
, Issue.11
, pp. 473
-
-
Wilson, J.M.1
Jungner, Y.G.2
-
4
-
-
70350450970
-
Prostate specific antigen best practice statement: 2009 update
-
Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5): 2232-41.
-
(2009)
J Urol.
, vol.182
, Issue.5
, pp. 2232-2241
-
-
Greene, K.L.1
Albertsen, P.C.2
Babaian, R.J.3
-
5
-
-
77949363162
-
American Cancer Society guideline for the early detection of prostate cancer: Update 2010
-
Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
-
(2010)
CA Cancer J Clin.
, vol.60
, Issue.2
, pp. 70-98
-
-
Wolf, A.M.1
Wender, R.C.2
Etzioni, R.B.3
-
6
-
-
67649446263
-
European Association of Urology position statement on screening for prostate cancer
-
Abrahamsson PA, Artibani W, Chapple CR, Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol. 2009;56(2):270-1.
-
(2009)
Eur Urol.
, vol.56
, Issue.2
, pp. 270-271
-
-
Abrahamsson, P.A.1
Artibani, W.2
Chapple, C.R.3
Wirth, M.4
-
7
-
-
33645128572
-
Brief report: Physicians and their personal prostate cancer-screening practices with prostatespecific antigen
-
Chan EC, Barry MJ, Vernon SW, Ahn C. Brief report: physicians and their personal prostate cancer-screening practices with prostatespecific antigen. A national survey. J Gen Intern Med. 2006;21(3): 257-9.
-
(2006)
A National Survey. J Gen Intern Med.
, vol.21
, Issue.3
, pp. 257-259
-
-
Chan, E.C.1
Barry, M.J.2
Vernon, S.W.3
Ahn, C.4
-
8
-
-
41549136821
-
Use of the prostate-specific antigen test among U. S. men:findings from the 2005 National Health Interview Survey
-
Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men:findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3):636-44.
-
(2008)
Cancer Epidemiol Biomarkers Prev.
, vol.17
, Issue.3
, pp. 636-644
-
-
Ross, L.E.1
Berkowitz, Z.2
Ekwueme, D.U.3
-
9
-
-
2642551798
-
Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study
-
Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94(1):51-6.
-
(2004)
BJU Int.
, vol.94
, Issue.1
, pp. 51-56
-
-
Melia, J.1
Moss, S.2
Johns, L.3
-
10
-
-
0025849053
-
Measurement of prostatespecific antigen in serum as a screening test for prostate cancer
-
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Eng J Med. 1991;324(17):1156-61.
-
(1991)
N Eng J Med.
, vol.324
, Issue.17
, pp. 1156-1161
-
-
Catalona, W.J.1
Smith, D.S.2
Ratliff, T.L.3
-
11
-
-
2442715038
-
Prevalence of prostate cancer among men with a prostate-specific antigen level £ 4. 0 ng per milliliter
-
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level £ 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
-
(2004)
N Engl J Med.
, vol.350
, Issue.22
, pp. 2239-2246
-
-
Thompson, I.M.1
Pauler, D.K.2
Goodman, P.J.3
-
12
-
-
0037016030
-
Screening for prostate cancer: An update of the evidence for the U. S. Preventive Services Task Force
-
Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917-29.
-
(2002)
Ann Intern Med.
, vol.137
, Issue.11
, pp. 917-929
-
-
Harris, R.1
Lohr, K.N.2
-
13
-
-
34249286193
-
Epidemiology of prostate cancer in Africa: Another step in the understanding of the disease?
-
Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer. 2007;31(3):226-36.
-
(2007)
Curr Probl Cancer.
, vol.31
, Issue.3
, pp. 226-236
-
-
Delongchamps, N.B.1
Singh, A.2
Haas, G.P.3
-
14
-
-
35148846265
-
Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence
-
Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484-9.
-
(2007)
J Natl Cancer Inst.
, vol.99
, Issue.19
, pp. 1484-1489
-
-
Haas, G.P.1
Delongchamps, N.B.2
Jones, R.F.3
-
15
-
-
49049090790
-
U.S. Preventative services task force. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement
-
U.S. Preventative Services Task Force. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-91.
-
(2008)
Ann Intern Med.
, vol.149
, pp. 185-191
-
-
-
16
-
-
63249118690
-
Screening and prostate-cancer mortality in a randomized European study
-
Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
-
(2009)
N Engl J Med.
, vol.360
, Issue.13
, pp. 1320-1328
-
-
Schröder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
17
-
-
78649362120
-
EAU guidelines on prostate cancer
-
Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
-
(2011)
Part 1: Screening, Diagnosis and Treatment of Clinically Localised Disease. Eur Urol.
, vol.59
, pp. 61-71
-
-
Heidenreich, A.1
Bellmunt, J.2
Bolla, M.3
-
19
-
-
37349005496
-
Characteristics of prostate cancer detected by digital rectal examination only
-
Okotie OT, Roehl KA, Han M, et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70(6):1117-20.
-
(2007)
Urology.
, vol.70
, Issue.6
, pp. 1117-1120
-
-
Okotie, O.T.1
Roehl, K.A.2
Han, M.3
-
20
-
-
70349667018
-
A systematic review of the diagnostic accuracy of prostate specific antigen
-
Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14-23.
-
(2009)
BMC Urol.
, vol.9
, pp. 14-23
-
-
Harvey, P.1
Basuita, A.2
Endersby, D.3
-
21
-
-
0027244140
-
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
-
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-4.
-
(1993)
JAMA.
, vol.270
, Issue.7
, pp. 860-864
-
-
Oesterling, J.E.1
Jacobsen, S.J.2
Chute, C.G.3
-
22
-
-
0028801975
-
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
-
Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273(4):289-94.
-
(1995)
JAMA.
, vol.273
, Issue.4
, pp. 289-294
-
-
Gann, P.H.1
Hennekens, C.H.2
Stampfer, M.J.3
-
23
-
-
23244433208
-
Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal
-
Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97(15):1132-7.
-
(2005)
J Natl Cancer Inst.
, vol.97
, Issue.15
, pp. 1132-1137
-
-
Welch, H.G.1
Schwartz, L.M.2
Woloshin, S.3
-
24
-
-
70349637766
-
Prostate specific antigen for early detection of prostate cancer: Longitudinal study
-
Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ. 2009;339:b3537.
-
(2009)
BMJ.
, vol.339
, pp. b3537
-
-
Holmstrom, B.1
Johansson, M.2
Bergh, A.3
Stenman, U.H.4
Hallmans, G.5
Stattin, P.6
-
25
-
-
31944436853
-
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old
-
Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67(2):316-20.
-
(2006)
Urology.
, vol.67
, Issue.2
, pp. 316-320
-
-
Loeb, S.1
Roehl, K.A.2
Antenor, J.A.3
Catalona, W.J.4
Suarez, B.K.5
Nadler, R.B.6
-
26
-
-
77956811462
-
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
-
Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521.
-
(2010)
BMJ.
, vol.341
, pp. c4521
-
-
Vickers, A.J.1
Cronin, A.M.2
Bjork, T.3
-
27
-
-
0141763756
-
Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam
-
van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam. J Natl Cancer Inst. 2003;95(19):1462-6.
-
(2003)
J Natl Cancer Inst.
, vol.95
, Issue.19
, pp. 1462-1466
-
-
Van Der Cruijsen-Koeter, I.W.1
Van Der Kwast, T.H.2
Schroder, F.H.3
-
28
-
-
34548581216
-
Interval cancers in prostate cancer screening: Comparing 2-and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam
-
Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2-and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam. J Natl Cancer Inst. 2007;99(17):1296-303.
-
(2007)
J Natl Cancer Inst.
, vol.99
, Issue.17
, pp. 1296-1303
-
-
Roobol, M.J.1
Grenabo, A.2
Schroder, F.H.3
Hugosson, J.4
-
29
-
-
63249122661
-
Mortality results from a randomized prostate-cancer screening trial
-
Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
-
(2009)
N Engl J Med.
, vol.360
, Issue.13
, pp. 1310-1319
-
-
Andriole, G.L.1
Crawford, E.D.2
Grubb, R.L.3
-
31
-
-
69249209651
-
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC)
-
Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC). Eur Urol. 2009;56(4):584-91.
-
(2009)
Eur Urol.
, vol.56
, Issue.4
, pp. 584-591
-
-
Roobol, M.J.1
Kerkhof, M.2
Schröder, F.H.3
-
32
-
-
33846271431
-
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial
-
Aus G, Bergdahl S, Lodding P, et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51:659-64.
-
(2007)
Eur Urol.
, vol.51
, pp. 659-664
-
-
Aus, G.1
Bergdahl, S.2
Lodding, P.3
-
33
-
-
77955279420
-
Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
-
Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-32.
-
(2010)
Lancet Oncol.
, vol.11
, Issue.8
, pp. 725-732
-
-
Hugosson, J.1
Carlsson, S.2
Aus, G.3
-
34
-
-
77952862416
-
ERSPC and PLCO prostate cancer screening studies: What are the differences?
-
Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46-52.
-
(2010)
Eur Urol.
, vol.58
, Issue.1
, pp. 46-52
-
-
Schroder, F.H.1
Roobol, M.J.2
-
35
-
-
0037027158
-
Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in twofixed cohorts from Seattle area and Connecticut
-
Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in twofixed cohorts from Seattle area and Connecticut. BMJ. 2002; 325(7367):740.
-
(2002)
BMJ.
, vol.325
, Issue.7367
, pp. 740
-
-
Lu-Yao, G.1
Albertsen, P.C.2
Stanford, J.L.3
Stukel, T.A.4
Walker-Corkery, E.S.5
Barry, M.J.6
-
36
-
-
56749163379
-
Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut:fifteen year follow-up
-
Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut:fifteen year follow-up. J Gen Intern Med. 2008;23(11):1809-14.
-
(2008)
J Gen Intern Med.
, vol.23
, Issue.11
, pp. 1809-1814
-
-
Lu-Yao, G.1
Albertsen, P.C.2
Stanford, J.L.3
-
37
-
-
8444233301
-
Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden
-
discussion 724
-
Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717-23; discussion 724.
-
(2004)
Eur Urol.
, vol.46
, Issue.6
, pp. 717-723
-
-
Sandblom, G.1
Varenhorst, E.2
Lofman, O.3
Rosell, J.4
Carlsson, P.5
-
38
-
-
0022460772
-
Fine needle aspiration biopsy of the prostate gland: A study of 103 cases with histological follow up
-
Ljung BM, Cherrie R, Kaufman JJ. Fine needle aspiration biopsy of the prostate gland: a study of 103 cases with histological follow up. J Urol. 1986;135(5):955-8.
-
(1986)
J Urol.
, vol.135
, Issue.5
, pp. 955-958
-
-
Ljung, B.M.1
Cherrie, R.2
Kaufman, J.J.3
-
39
-
-
1942539318
-
Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial
-
Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311-8.
-
(2004)
Prostate.
, vol.59
, Issue.3
, pp. 311-318
-
-
Labrie, F.1
Candas, B.2
Cusan, L.3
-
40
-
-
33748082979
-
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostatespecific antigen testing
-
Oberaigner W, Horninger W, Klocker H, et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostatespecific antigen testing. Am J Epidemiol. 2006;164(4):376-84.
-
(2006)
Am J Epidemiol.
, vol.164
, Issue.4
, pp. 376-384
-
-
Oberaigner, W.1
Horninger, W.2
Klocker, H.3
-
41
-
-
0002855014
-
1931-1971: A critical review, with particular reference to the medical profession
-
London: Office of Health Economics
-
Cochrane AL. 1931-1971: a critical review, with particular reference to the medical profession. In: Medicines for the year 2000. London: Office of Health Economics; 1979. p. 1-11.
-
(1979)
Medicines for the Year 2000
, pp. 1-11
-
-
Cochrane, A.L.1
-
43
-
-
77956810216
-
Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials
-
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
-
(2010)
BMJ.
, vol.341
, pp. c4543
-
-
Djulbegovic, M.1
Beyth, R.J.2
Neuberger, M.M.3
-
44
-
-
0037014792
-
Overdiagnosis due to prostate-specific antigen screening: Lessons from U. S. Prostate cancer incidence trends
-
Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. Prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-90.
-
(2002)
J Natl Cancer Inst.
, vol.94
, Issue.13
, pp. 981-990
-
-
Etzioni, R.1
Penson, D.F.2
Legler, J.M.3
-
45
-
-
70349941075
-
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
-
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-9.
-
(2009)
J Natl Cancer Inst.
, vol.101
, Issue.19
, pp. 1325-1329
-
-
Welch, H.G.1
Albertsen, P.C.2
-
46
-
-
64949135826
-
Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context
-
Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-83.
-
(2009)
J Natl Cancer Inst.
, vol.101
, Issue.6
, pp. 374-383
-
-
Draisma, G.1
Etzioni, R.2
Tsodikov, A.3
-
47
-
-
0038275923
-
Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer
-
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst. 2003;95(12):868-78.
-
(2003)
J Natl Cancer Inst.
, vol.95
, Issue.12
, pp. 868-878
-
-
Draisma, G.1
Boer, R.2
Otto, S.J.3
-
48
-
-
4644287961
-
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study
-
Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358-67.
-
(2004)
J Natl Cancer Inst.
, vol.96
, Issue.18
, pp. 1358-1367
-
-
Potosky, A.L.1
Davis, W.W.2
Hoffman, R.M.3
-
49
-
-
70449525320
-
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
-
Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79-85.
-
(2010)
Eur Urol.
, vol.57
, Issue.1
, pp. 79-85
-
-
Roobol, M.J.1
Steyerberg, E.W.2
Kranse, R.3
-
50
-
-
33845312324
-
External validation of the prostate cancer prevention trial risk calculator in a screened population
-
Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology. 2006;68(6):1152-5.
-
(2006)
Urology.
, vol.68
, Issue.6
, pp. 1152-1155
-
-
Parekh, D.J.1
Ankerst, D.P.2
Higgins, B.A.3
-
51
-
-
34547736129
-
Risk factors for prostate cancer incidence and progression in the health professionals follow-up study
-
Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7): 1571-8.
-
(2007)
Int J Cancer.
, vol.121
, Issue.7
, pp. 1571-1578
-
-
Giovannucci, E.1
Liu, Y.2
Platz, E.A.3
Stampfer, M.J.4
Willett, W.C.5
-
52
-
-
18544377048
-
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1
-
Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30(2):181-4.
-
(2002)
Nat Genet.
, vol.30
, Issue.2
, pp. 181-184
-
-
Carpten, J.1
Nupponen, N.2
Isaacs, S.3
-
53
-
-
0037222306
-
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
-
Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1-12.
-
(2003)
Am J Hum Genet.
, vol.72
, Issue.1
, pp. 1-12
-
-
Edwards, S.M.1
Kote-Jarai, Z.2
Meitz, J.3
-
54
-
-
78650657873
-
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study
-
Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011;107(1):28-39.
-
(2011)
BJU Int.
, vol.107
, Issue.1
, pp. 28-39
-
-
Mitra, A.V.1
Bancroft, E.K.2
Barbachano, Y.3
-
55
-
-
58549118238
-
Prostate cancer genomics: Towards a new understanding
-
Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet. 2009;10(2):77-82.
-
(2009)
Nat Rev Genet.
, vol.10
, Issue.2
, pp. 77-82
-
-
Witte, J.S.1
-
56
-
-
39749129053
-
Multiple newly identified loci associated with prostate cancer susceptibility
-
Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-21.
-
(2008)
Nat Genet.
, vol.40
, Issue.3
, pp. 316-321
-
-
Eeles, R.A.1
Kote-Jarai, Z.2
Giles, G.G.3
-
57
-
-
78149451143
-
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
-
Whitaker HC, Kote-Jarai Z, Ross-Adams H, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010;5(10):e13363. doi: 10.1371/journal.pone.0013363 .
-
(2010)
PLoS One.
, vol.5
, Issue.10
, pp. e13363
-
-
Whitaker, H.C.1
Kote-Jarai, Z.2
Ross-Adams, H.3
|